Semax is a fragment of a stress hormone, Selank is a fragment of an immune peptide, and that ancestry predicts almost everything about how each one behaves. Semax pushes neurotrophins, Selank pushes GABAergic and inflammatory gene expression. Choose between them on which mechanism you want and you will get the answer most articles give.
The answer I would rather give is that both bodies of evidence share the same ceiling: nearly all of it is animal work or Russian-language clinical reports, and the difference between the two compounds is smaller than the difference between that literature and what a Western trial would require.
Different parents, different behaviour
Semax is a synthetic analogue of the ACTH(4-10) fragment, characterised in work measuring its behavioural and neurochemical effects in animals.[1] Its parent molecule is adrenocorticotropic hormone, a stress-axis signal, with the hormonal activity engineered out and the neural activity kept.
Selank belongs to the family of synthetic analogues of tuftsin,[2] an immunomodulatory peptide. Different parent, different family, and the immune ancestry shows up directly in what it does.
Head to head on mechanism
This is where the two genuinely separate, and both stories are preclinical.
Semax acts on neurotrophins. It regulated BDNF and trkB expression in rat brain, in work that also reported cognitive effects.[3] BDNF is the growth-factor pathway most associated with learning and synaptic plasticity, which is why the cognitive framing attached to Semax rather than to Selank.
Selank acts on GABA and on inflammation. Selank administration affected the expression of genes involved in GABAergic neurotransmission in animals,[4] which is the same neurotransmitter system benzodiazepines act on, by a completely different route. Its immune inheritance is visible too: Selank changed expression of inflammation-related genes in mouse spleen.[5]
The mechanistic split is real: Semax is a neurotrophin story, Selank is a GABA-and-inflammation story. Both are gene-expression findings in rodents, and neither has been confirmed as the operative mechanism in a person.
Head to head on human evidence
Both have human data. It is the same kind of human data, and its character is the most important fact in this comparison.
Semax was examined in patients at different stages of ischaemic stroke in Russian-language clinical research.[6] Neurological recovery, real patients, published in Russian.
Selank was examined in patients with generalised anxiety disorder in a Russian-language randomized study.[7] A randomized design, a defined clinical population, published in Russian.
Selank’s human study is the better one on design alone, because it was randomized and the Semax stroke work was not. That is the honest head-to-head verdict on evidence quality, and it is a narrow win in a small field.
What neither has: a large randomized trial published outside the Russian literature, a replication by an independent group in another country, or any study in healthy adults taking them for cognition or mood, which is what almost everyone buying them is doing.
Head to head on delivery
Both are used intranasally, and that route is doing real pharmacological work rather than being a convenience.
Nose-to-brain delivery is used to reach the brain without crossing the blood-brain barrier from the circulation.[8] For a peptide this matters enormously, because a peptide injected into a vein has almost no chance of reaching brain tissue intact.
The catch is the same for both compounds: how much of a nasally administered peptide reaches brain tissue remains uncertain.[9] The route is plausible and it is not quantified, which means no dose quoted for either compound corresponds to a known brain exposure.
Neither compound has a published dose-ranging study in healthy adults. Every protocol circulating for either is convention.
Choose by mechanism, and know what you are choosing
Choose Semax if the neurotrophin pathway is the mechanism you want. Its preclinical work is specifically about BDNF and trkB, and its human data, such as it is, comes from neurological recovery rather than from mood.
Choose Selank if anxiety is the target. Its GABAergic gene-expression finding fits the use case, and it has the better-designed human study of the two, randomized and in a defined psychiatric population.
Do not choose between them on the strength of the evidence. Both rest on rodent gene expression and a Russian clinical literature that no independent group has replicated. That is not an accusation against the research, which is real work by real laboratories. It is a statement about what one country’s unreplicated literature can support.
Bottom line: Selank has the better human study, Semax has the better-characterised mechanism, and the gap between either of them and a compound with Western phase 3 evidence is far wider than the gap between the two. If you want the one with a randomized trial in the population it is sold for, that is Selank. If you want certainty, neither is on offer.
This article is for research and informational purposes only and is not intended to diagnose, treat, cure, or prevent any disease. The peptides discussed here are sold for research use only and are not for human consumption. Nothing in this article constitutes medical advice. Consult a qualified clinician before making changes to a health, training, or supplementation protocol.
References
Semax, synthetic ACTH(4-10) analogue, attenuates behavioural and neurochemical alterations following early-life fluvoxamine exposure in white rats.. Neuropeptides, 2021.
Tuftsin - Properties and Analogs.. Current medicinal chemistry, 2017.
Semax, an analog of ACTH(4-10) with cognitive effects, regulates BDNF and trkB expression in the rat hippocampus.. Brain research, 2006.
Selank Administration Affects the Expression of Some Genes Involved in GABAergic Neurotransmission.. Frontiers in pharmacology, 2016.
Expression of inflammation-related genes in mouse spleen under tuftsin analog Selank.. Regulatory peptides, 2011.
[The efficacy of semax in the tretament of patients at different stages of ischemic stroke].. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova, 2018.
[Efficacy and possible mechanisms of action of a new peptide anxiolytic selank in the therapy of generalized anxiety disorders and neurasthenia].. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova, 2008.
Nose-to-Brain Delivery of Therapeutic Peptides as Nasal Aerosols.. Pharmaceutics, 2022.
Insulin Delivery to the Brain via the Nasal Route: Unraveling the Potential for Alzheimer's Disease Therapy.. Drug delivery and translational research, 2024.
